


Talniflumate

Cat. No.:	HY-103370		
CAS No.:	66898-62-2		
Molecular Formula:	C ₂₁ H ₁₃ F ₃ N ₂ O ₄		
Molecular Weight:	414.33		
Target:	Chloride Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (201.12 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.4135 mL	12.0677 mL	24.1354 mL
	5 mM	0.4827 mL	2.4135 mL	4.8271 mL
	10 mM	0.2414 mL	1.2068 mL	2.4135 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	Talniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase ^[1] . Talniflumate is an orally active Ca ²⁺ -activated Cl ⁻ channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome ^[2] .
IC₅₀ & Target	IC ₅₀ : Ca ²⁺ -activated Cl ⁻ channel (CaCC) ^[1]
In Vivo	Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	CF mice with distal intestinal obstructive syndrome (DIOS) ^[1]

Dosage:	0.4 mg/g
Administration:	Oral chow; 21 days
Result:	Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.

REFERENCES

- [1]. Hyun-Ji Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Archives of Pharmacal Research volume 19, Article number: 297 (1996)
- [2]. Mollereau, et al. Agonist and Antagonist Activities on Human NPFF(2) Receptors of the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001 May;133(1):1-4.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA